

## Research Activities Newsletter

The latest news and announcements



### In This Issue

In the News: Congratulations to the following awardees!!! .....	2
General Notice .....	3
Notice of Intent to Publish .....	4
Notice of Special Interest .....	4
Policy Notices.....	5
NIH Funding Opportunities: Request for Applications (RFA).....	6
• Addictions.....	6
• Cancer .....	6
• HIV/AIDS .....	7
NIH Funding Opportunities (PAR).....	8
• Addictions.....	8
• Cancer .....	8
• Miscellaneous .....	8
NIH Funding Opportunities: Program Announcements (PA) .....	9
Limited Submissions .....	10
Research Opportunities from Past Newsletters .....	10
Words to Live By .....	10

## In the News: Congratulations to the following awardees!!!



**Matt Bonner**, Associate Professor of Epidemiology and Environmental Health (EEH), is PI on a new award from the University of Iowa/NIH for the project entitled, *Adolescent Insecticide Exposure and ADHD Risk: Mechanisms of Immediate Effects and Ongoing Vulnerability*. This project will test three synergistic aims joining human investigation and animal mechanistic assessments with translation between them. **James Olsen**, UB Distinguished Professor of Epidemiology and Environmental Health (EEH) is Co-I on the project.



**Nicholas Felicione**, Assistant Professor of Community Health and Health Behavior (CHHB), is PI on a new award from Health Research Inc./NIH for the project entitled, *Predicting and Understanding the Use of Nicotine Products in a Rapidly Evolving Nicotine Marketplace: The International Nicotine Project, Policy, and market (INPAM) Study – Emerging Projects Core*. The goal of this P01 renewal application is to address the question “What have different countries done to regulate tobacco products and how has this impacted tobacco use behaviors?” We plan to analyze and compare the experiences of different countries with varying regulatory approaches to inform United States public policy, based upon the best science available to maximize population health.



**Akua Gyamerah**, Assistant Professor of Community Health and Health Behavior (CHHB), is PI on a new award from the West Africa AIDS Foundation for the research project entitled, *A Comprehensive Assessment of the Health Prevention Needs of the Transgender Population in Ghana*. This project will access the availability of HIV combination prevention interventions, explore the barriers to accessing HIV services, sexual, mental, reproductive, and other healthcare needs faced by trans people in Ghana. It will also investigate the health-seeking experiences of trans people for HIV services, and other services within the wider healthcare system in Ghana.



**Michael LaMonte**, Research Professor of Epidemiology and Environmental Health (EEH), is PI on a continuation of his award from Kent County Memorial Hospital/NIH for the project entitled, *Racial/Ethnic Disparities in Heart Failure: A Cross Cohort Collaboration*. The study proceeds to evaluate the magnitude and potential causes of racial/ethnic and sex disparities in incident heart failure and its subtypes and their prognosis in 130,000 men and women from 10 pooled cohorts.



**Douglas Landsittel**, Professor and Chair of Biostatistics, is PI on the continuation of his award from the University of Pittsburgh/NIH for the project entitled, *Regulatory Dendritic Cell Therapy in Live Donor Renal Transplant Recipients*. This study aims 1) to conduct a first-in-human, open label, single center phase 1 dose escalation safety study in adult recipients of de novo, live donor renal transplants and 2) conduct sequential immunological analyses of the DCREG recipients.



**Vijaya Prakash Krishnan Muthaiah**, Assistant Professor of Rehabilitation Science (RS) lead PI, **Katarzyna Kordas**, Associate Professor of Epidemiology and Environmental Health (EEH) and **Lili Tian**, Associate Chair and Professor of Biostatistics MPI's on their new award from NIOSH/centers for Disease Control and Prevention for the research project entitled, *Hearing Loss by the Synergistic Effect of Chronic Inhalation of Exposure of Manganese Fumes with Occupational Noise Exposure*. The central objective of the proposed study is to determine if chronic inhalation of Mn fumes induces hearing loss and if it has a synergistic effect with concurrent occupational noise exposure. **Meng Wang**, Associate Professor of Epidemiology and Environmental Health is Co-I on the project.





**Jean Wactawski-Wende**, Dean of SPHHP and SUNY Distinguished Professor of Epidemiology and Environmental Health (EEH) is PI on a continuation of the award from the National Heart, Lung and Blood Institute/NIH for the research project entitled, *Women's Health Initiative – Regional Center*. As the Northeast Regional Center for the WHI, the study continues to collect health outcomes and new risk factor data in the postmenopausal women who have been participants since the study was launched in 1993. With 70,000 remaining active participants now aged between 78 and 103 years, the extension award will continue to focus on heart failure, atrial fibrillation, VTE, coronary heart disease, peripheral arterial disease (PAD), stroke and sleep disorders, as well as assess dementia, fracture, falls, physical function, and mortality. Co-Investigators from EEH are **Hailey Banack**, Research Assistant Professor, **Michael LaMonte**, Research Professor, **Amy Millen**, Associate Professor, and **Heather Ochs-Balcom**, Associate Professor.



**Gregory Wilding**, Professor of Biostatistics, is Co-I on a new award from the National Cancer Institute/NIH (PI: Eunhee Park, School of Nursing) for the project entitled, *AI-Enhanced App-based Intervention for Adolescent E-Cigarette Cessation*. This study is aimed at creating a scalable e-cigarette use cessation intervention using a smartphone application (app), which can be delivered to a large pool of adolescents. This study will develop and test a scalable smartphone AI-enhanced app-based intervention delivery that can be feasibly implemented in schools, primary care clinics and community settings for adolescent e-cigarette cessation.



**Jihnhhee Yi**, Professor of Biostatistics, is Co-I on a new award from the National Institute of Aging/NIH (PI: Carleara Weiss, School of Nursing) for the project entitled, *The Benefits of Nicotinamide Riboside Upon Cognition and Sleep in Older Veterans*. The overarching goal is to investigate the role of sleep disturbances as a candidate mechanism of cognitive impairment and neurodegeneration. During the R00 phase, the study team proposes to investigate the relationship between NAD<sup>+</sup> serum levels and biomarkers of neurodegeneration.

## General Notices

### [NOT-OD-24-165](#) – Retirement of NIH's Automated Just-in-time Email Notification

This Guide Notice informs the extramural research community that the eRA system-generated email notification announcing the availability to submit Just-in-Time information for an application in eRA Commons will be retired as of October 1, 2024. This change has no impact on an applicant's ability to submit Just-in-Time information upon request from staff at the awarding institute or center. As mentioned in [NOT-OD-12-101](#), NIH has continued to review the automated JIT notification trigger level to determine if additional adjustments are needed to improve the process. Based on feedback we have received over the past 12 years from our internal and external stakeholders, we have determined that the automated JIT notification is no longer needed.

### [NOT-OD-24-169](#) – Updating the Definition of Sexual and Gender Minority Populations in NIH-Supported Research

This notice announces a revision to the definition of sexual and gender minority (SGM) populations for NIH-supported research effective September 6, 2024.

### [NOT-DK-24-026](#) – Research Strategies for Addressing Obesity Heterogeneity

This Request for Information invites input on research strategies to address obesity heterogeneity in the US. It is intended to solicit input from a broad array of interested individuals, groups and communities including the biomedical and behavioral research community, physicians and other health care professionals, industry, and other interested parties including public health or social service officials at the federal, state, county and community levels, community organizations, those in educational settings, payers, media, advocacy groups and the general public. Endotyping is already being applied or explored in a number of complex diseases. Given that this approach has not been widely used in obesity, NIH staff have been reflecting on the types of research needed to develop obesity endotypes and endophenotypes, algorithms to detect them, enhance prediction of efficacious treatment for individual patients, and improve prediction of susceptibility for development of obesity-related co-morbidities.



## Notice of Intent to Publish

### [NOT-LM-24-003](#)

#### **Notice of Intent to Publish a Funding Opportunity Announcement for Computational Approaches to Curation at Scale for Biomedical Research Assets (R01 Clinical Trial Not Allowed)**

The National Library of Medicine (NLM) intends to reissue [PAR-20-304](#) for "Computational Approaches to Curation at Scale for Biomedical Research Assets (R01 Clinical Trial Not Allowed)." NLM wishes to accelerate access to, and availability of, secure, complete datasets and computational models that can serve as the basis for transformative biomedical discoveries. Innovative at-scale computational approaches that increase the speed and scope of curation processes are needed for data mining and knowledge discovery from growing quantities of biomedical data produced from ongoing data science advances. **This NOFO is expected to be published in the Fall of 2024 with an expected first due date on February 05, 2025.**

### [NOT-CA-24-096](#) – (R01 Clinical Trial Optional)

### [NOT-CA-24-097](#) – (R21 Clinical Trial Optional)

#### **Notice of Intent to Publish a Funding Opportunity Announcement for Tobacco, Alcohol, and Cannabis Policy Research for Health Equity**

The National Cancer Institute intends to promote a new initiative by publishing a NOFO to solicit applications for policy research projects that focus on disparities in tobacco, alcohol, and cannabis exposure and/or use by examining new or adapted policies pertaining to tobacco, alcohol, and/or cannabis in the U.S. The results of funded projects will advance equitable tobacco, alcohol, and cannabis policies. The NOFO is expected to be published in September 2024 with an expected first application due date in February 2025.

### [NOT-DA-24-046](#) – (R01 Clinical Trial Not Allowed)

### [NOT-DA-24-047](#) – (R21 Clinical Trial Not Allowed)

#### **Notice of Intent to Publish a Funding Opportunity Announcement for Accelerating the Pace of Substance Use Research Using Existing Data**

The NIDA intends to promote the reissue of an initiative by publishing a NOFO to solicit applications for research on Accelerating the Pace of Substance Use Research Using Existing Data. Strongly encouraged is the application of innovative methods, big data analytics, computational modeling, artificial intelligence, or techniques from other disciplines that are novel to substance use and disorder research; use of multiple sources of data towards predicting substance use behaviors and solutions; or access and utilization of real-time or close to real-time data. The NOFO is expected to be published in Fall 2024 with an expected application due date in Spring 2025.

### [NOT-OD-25-002](#) – (R01 Clinical Trial Optional)

#### **Notice of Intent to Publish a Notice of Funding Opportunity for High-Priority Research in Tobacco Regulatory Science**

This notice is to inform the extramural research community that the NIH Tobacco Regulatory Science Program (TRSP), participating NIH Institutes and Centers (ICs), and the United States Food and Drug Administration Center for Tobacco Products (CTP) intend to issue a NOFO seeking research applications for new High-Priority Research in Tobacco Regulatory Science. Applications will support new high-priority biomedical and behavioral research that will provide scientific data to inform the regulation of tobacco products to protect public health. This NOFO will include the new [simplified peer review framework](#) (SRF) and the [Plan for Enhancing Diverse Perspective](#). Please see announcement for list of high-priority research topics. The NOFO is expected to be published in Winter 2024, with an expected application due date in Summer 2025.

## Notice of Special Interest

### [NOT-DA-26-008](#)

#### **Research on Illicit Drug Markets**

The purpose of this notice is to encourage research that examines illicit drug markets and informs prevention, intervention, treatment, and harm reduction efforts. Applications are strongly encouraged to consider who the end-users of the research findings will be (e.g., policy-makers, prevention scientists, local health departments, etc.), and if/when appropriate, include possible end-users in the research team to ensure that the knowledge generated will have real-world impact. This NOSI's



primary interest is U.S. illicit drug markets; however, research involving international illicit drug markets will be considered in the context of the impacts and influences they have on U.S. drug markets, drug use, or substance-related harms. This notice applies to due dates on or after October 5, 2024 and subsequent receipt dates through September 8, 2028.

#### [NOT-DA-26-004](#)

##### **Training Program in Application of Artificial Intelligence in Development of Treatment for Substance Use Disorders**

The purpose of this NOSI is to support workforce development and training in AI/ML to grow new generation of data scientists and promote data science literacy among researchers developing treatments for SUDs. Please see notice for areas of interest. This notice applies to due dates on or after June 12, 2025 and subsequent receipt dates through September 8, 2028.

#### [NOT-MD-24-022](#)

##### **Effectiveness of Mobile Health Clinics to Advance Health Equity**

This initiative will support innovative multidisciplinary collaborative research designed to investigate the effectiveness of Mobile Health Clinics (MHCs) in improving healthcare access and addressing the health care needs of populations that experience health disparities and whether they result in improved health outcomes and increased health equity. Projects across the lifespan including children (under 18 years), adults (18 – 64 years), and/or older adults (65 years and older) are encouraged. Please see notice for areas of interest as well as application and submission information.

#### [NOT-OD-24-179](#)

##### **Research on the Health of Women of Underrepresented, underserved, and Underreported (U3) Populations (Admin Supp Clinical Trial Optional)**

The Office of Research on Women's Health (ORWH) announces the availability of administrative supplements to support research to address health disparities among women in the United States who are underrepresented, underserved, and underreported (U3) in biomedical research. This NOSI encourages rigorous, collaborative, interdisciplinary research on the differential risk, treatment outcomes, and morbidity experienced by populations of women who are underrepresented, underserved, and underreported in biomedical research across the lifespan. **Application Due Dates:** January 22, 2025 and January 22, 2026.

## Policy Notices

#### [NOT-OD-24-163](#) – **NIH's Adoption of Common Forms for Biographical Sketch and Current and Pending (Other) Support by May 25, 2025**

The Common Forms represent a collaborative effort between federal research agencies to ensure standard disclosure requirements as outlined in the [National Security Presidential Memorandum - 33](#). The approved Common Forms for Biographical Sketch and Current and Pending (Other) Support (OMB Number 3145-0279 managed by the U.S. National Science Foundation (NSF)), can be accessed at NSF's website at [NSTC Research Security Subcommittee NSPM-33 Implementation Guidance Disclosure Requirements & Standardization](#). *NIH Common Forms Implementation* - NIH will implement the Common Forms without change to any collection fields. However, in accordance with NIH's Peer Review Regulations at [42 Code of Federal Regulations Part 52h](#), NIH currently plans to continue collecting three required agency specific data elements (i.e., Personal Statement, Contributions to Science, and Honors) to assess qualifications. **These data elements will be collected separately from the Common Forms on a new NIH Biographical Sketch Supplement.** Please see notice for additional information.

#### [NOT-OD-24-175](#) – **Reminder – Reporting Data Management and Sharing (DMS) Plan Activities in Research Performance Progress Reports (RPPRs) Submitted on or After October 1, 2024**

The purpose of this Notice is to remind the research community of the requirement to address the NIH Data Management and Sharing Policy in Research Performance Progress Reports (RPPRs) submitted on or after October 1, 2024, and to provide additional details about the implementation of the RPPR instructions. On October 1, 2024, NIH will issue new DMS questions that align with the [NIH Final Policy on Data Management and Sharing](#), asking recipients for updates on the status of data sharing, repositories, and unique identifiers for data that have been shared. Please see notice for the overview of changes.



### [NOT-OD-24-176](#) – Updated Processes for Requesting Revisions to an Approved Data Management and Sharing (DMS) Plan

The purpose of this notice is to inform the extramural research community of updates to the processes for submitting requests to revise a Data Management and Sharing (DMS) Plan through the Just in Time (JIT) Module, the Prior Approval Module, and the RPPR Module in eRA Commons. This updated functionality will be available for NIH grants subject to the Final NIH Policy for Data Management and Sharing (DMS) Policy effective October 1, 2024, and will be used exclusively for submitting requests for updating the DMS Plan. As a reminder, emails and other communications are not acceptable. Please see notice for additional information on the process for submitting requests and revising DMS Plans.

### [NOT-OD-24-178](#) – Final Scientific Integrity Policy of the National Institutes of Health

The purpose of this guide notice is to issue the Final NIH Scientific Integrity Policy to promote a continuing culture of scientific integrity at NIH. This Policy codifies NIH's long-standing expectations to preserve scientific integrity throughout all NIH activities, establishes key roles and responsibilities for those who will lead the agency's scientific integrity program, and, as appropriate, establishes relevant reporting and evaluation mechanisms. NIH released its Request for Information on the Draft NIH Scientific Integrity Policy on September 25, 2023 ([88 FR 65696](#), comment period closed on November 9, 2023). In response to the Draft Policy, NIH received 26 responses from interested parties, and the comments are [publicly available](#). This policy goes into effect on December 30, 2024. This policy will be evaluated by NIH one year after its effective date and every two years thereafter. For more in-depth details on policy amendments, please click on link to notice.

## NIH Funding Opportunities: Request for Applications (RFA)

### Addictions

[RFA-NS-25-020](#) – (R01 Clinical Trial Optional)

#### **HEAL Initiative: Understanding Individual Differences in Human Pain Conditions**

This notice from the [NIH's Helping to End Addiction Long-term® \(HEAL\) Initiative](#) aims to support research aimed at holistic understanding of inter-individual or between-person differences in human pain conditions, focusing on 'Whole Person Health' and enhancing pain treatment and management strategies. The goal of this NOFO is to support studies that focus on the collection of clinical and/or preclinical data to enable evidence-based modeling and understanding of inter-individual differences and/or heterogeneity of pain occurring with use of pain therapy/management, or with conditions such as a second pain condition, a comorbid health condition, a comorbid mental health condition, or conditions of use / misuse of opioids, alcohol or other substances. This NOFO encourages investigators to pursue challenging research addressing inter-individual or between-person differences observed in pain perception, pain severity, NIH HEAL core pain domains, treatment effectiveness/responsiveness, and/or the impact of comorbidities, including a biopsychosocial context to conceptualize and study inter-individual differences in responses to pain and its treatment, focusing on 'whole person health'. **Application Due Date:** February 6, 2025. **Expiration Date:** February 7, 2025.

### Cancer

[RFA-CA-25-011](#) – (R01 Clinical Trial Optional)

[RFA-CA-25-012](#) – (R21 Clinical Trial Optional)

#### **The Confluence of Cancer Stigma in HIV-positive Individuals Diagnosed with Cancer**

Through this NOFO as a request for applications, the National Cancer Institute intends to support research that expands the current understanding of the confluence of cancer stigma and HIV stigma among people with HIV (PWH) diagnosed with cancer; assesses the impact of these two converging stigmas on cancer outcomes among PWH with cancer; leverages stigma reduction interventions at multiple levels to intervene on modifiable mechanisms of stigma that contribute to negative cancer outcomes among PWH with cancer; and promotes research in domestic and international contexts, focusing on regions in which the HIV-cancer burden is elevated. Whereas this NOFO is for well-developed projects supported by preliminary data, there is a companion NOFO ([RFA-CA-25-012](#)) of identical scientific scope meant for pilot/exploratory projects. **Application Due Date:** December 10, 2024. **Expiration Date:** December 11, 2024.

[RFA-CA-25-010](#) – (UG3/UH3 Clinical Trial Required)



**Scaling-up and Maintaining Evidence-based Interventions to Maximize Impact on Cancer (SUMMIT) – Tobacco Use Treatment for Cancer Survivors**

This notice of funding opportunity invites proposals for Research Projects to advance the science of scale-up and sustainment of tobacco use treatment (TUT) for cancer survivors. Each Research Project will propose a trial to test implementation strategies to equitably and effectively scale-up and sustain the delivery of TUT to a large number of diverse clinical care delivery settings and cancer survivor populations, with an emphasis on cancer survivor populations experiencing health inequities. **Application Due Date:** December 6, 2024. **Expiration Date:** December 7, 2024.

[RFA-CA-25-013](#) – (UG3/UH3 Clinical Trial Not Allowed)

**Discovery and Development of Natural Products for Cancer Interception and Prevention**

Through this notice, the National Cancer Institute intends to support the discovery and development of novel natural products that are safe, non-toxic, and efficacious for cancer interception and prevention. Through this NOFO, NCI solicits applications that propose the identification of cancer preventive natural products using the commercial natural product libraries or investigator owned libraries or the NCI Program for Natural Product Discovery (NPNPD) Pre-fractionated Natural Product Library and the NCATS resources. **Application Due Date:** June 13, 2025. **Expiration Date:** June 14, 2025.

**HIV/AIDS**

[RFA-HD-25-003](#) – (U19 Clinical Trial Not Allowed)

**Pediatric HIV/AIDS Cohort Study (PHACS)**

The purpose of this NOFO is to support the Pediatric HIV/AIDS Cohort Study (PHACS) cohorts as a transformative, streamlined, and agile program addressing the developmental and clinical course of persons living with HIV and perinatally acquired HIV in the US. The goals of this initiative are to support research on the developmental and clinical course of persons living with HIV and perinatally acquired HIV, including the effects of HIV and HIV treatment on fertility, pregnancy and post-partum outcomes, complications, co-morbidities, and co-infections including gynecologic conditions and sexually transmitted infections (STI's) for example syphilis, chlamydia, gonorrhea, HPV, trichomoniasis and CMV. Early changes in oral health, alcohol, and substance use, behavioral, mental, social, health outcomes may also be evaluated. **Application Due Date:** December 11, 2024. **Expiration Date:** December 12, 2024.

**Miscellaneous**

[RFA-AT-25-001](#) – (R15 Clinical Trial Optional)

**HEAL Initiative: Pain Research Enhancement Program (PREP)**

The purpose of this HEAL Initiative program is to: (1) support basic and mechanistic pain research from R15-eligible undergraduate-focused serving institutions, health professional schools or graduate schools; (2) promote integrated, interdisciplinary research partnerships between Principal Investigators (PIs) from R15-eligible institutions and investigators from U.S. domestic institutions; and (3) enhance the pain research environment at the R15-eligible institution for health professional students, undergraduate and/or graduate students through active engagement in pain research. **Application Due Dates:** October 28, 2025 and October 27, 2026. **Expiration Date:** November 23, 2026.

[RFA-NR-25-001](#) – R01 Clinical Trial Optional)

**Advancing Health Equity through Interventions to Prevent and Address Housing Instability**

The purpose of this funding opportunity is to support research that advances health equity through development, testing, and evaluation of interventions that prevent and address housing instability. Applications responding to this Notice of Funding Opportunity should develop, test, and/or evaluate the impact of a housing intervention on both health and housing outcome(s). NINR is interested in applications that focus on social determinants of health (SDOH) interventions that modify housing opportunities and/or interventions that address housing instability as a social risk by addressing individual and/or interpersonal-level housing needs. **Application Due Date:** December 13, 2024. **Expiration Date:** December 14, 2024.



## NIH Funding Opportunities (PAR)

### Addictions

[PAR-24-298](#) – (R21 Clinical Trial Optional)

#### **Mechanism for Time-Sensitive Substance Use Research**

This notice will support pilot, feasibility or exploratory research in priority areas in substance use epidemiology, prevention, and health services, including: 1) Research in response to sudden and severe emerging drug issues; 2) Research in response to emerging trends and topics related to a change in federal, state, or local drug policy. 3) Research in response to unexpected and time-sensitive medical system issues; 4) Responses to unexpected and time-sensitive criminal or juvenile justice opportunities that relate to drug misuse and access and provision of health care service; 5) Research that examines the early implementation of new or newly changed federal, state, or local programs, policy, financing, or payment approaches related to substance use, substance use epidemiology, prevention, treatment, or recovery; 6) Research in response to natural disasters or newly emergent public health emergencies, to understand their impacts on drug markets, substance use epidemiology, prevention, treatment or recovery outcomes. This NOFO responds to the need for rapid responses to emerging policy changes and phenomena that affect the delivery and/or effectiveness of prevention and treatment services related to addiction care (in particular prescription drug use), HIV care, and the criminal justice setting.

**Application Due Date:** multiple dates; see announcement. **Expiration Date:** September 10, 2027.

### Cancer

[PAR-24-274](#) – (R50 Clinical Trial Not Allowed)

#### **NCI Research Specialist (Clinician Scientist) Award**

Through this NOFO, the National Cancer Institute invites applications for the Research Specialist Award specifically for clinician scientists supporting NCI-funded clinical trials research. This award is designed to encourage the development of stable research career opportunities for exceptional clinician scientists who want to continue to participate in the NCI clinical trials networks through leadership in the 1) development of national clinical trials, 2) implementation of NCI clinical trials in their institutions, and 3) national service to the NCI clinical trials networks through participation in the scientific review committees, monitoring committees and other activities, but not serve as principal investigators of research project grants.

**Application Due Date:** November 4, 2025. **Expiration Date:** November 5, 2025.

[PAR-25-098](#) – (R01 Clinical Trial Required)

#### **Interventions to Expand Cancer Screening and Preventive Services to ADVANCE Health in Populations that Experience Health Disparities**

The Office of Disease Prevention and participating NIH Institutes, Centers, and Offices (ICs) are issuing this announcement to solicit applications to address barriers and facilitators that impede use or uptake of cancer screening and preventive services in populations that experience health disparities. Interventions should include screening, preventive services, or other healthcare processes, including timely follow-up of abnormal findings, and referral to accessible care. Projects are encouraged to leverage collaborations with community partners and service providers. Interventions should address barriers and facilitators at two or more of the following levels: patient, clinician, healthcare setting, and neighborhood/community.

**Application Due Date:** multiple dates; see announcement. **Expiration Date:** January 8, 2027.

### Miscellaneous

[PAR-24-281](#) – (G08 Clinical Trial Not Allowed)

#### **NLM Information Resource Grants to Reduce Health Disparities and Promote Health Equity**

This NOFO solicits resource grant applications for projects that will provide accurate, useful, usable, and understandable health information to populations that experience health disparities and their health care providers. This notice supports the development of resources that can be used to make decisions that improve health and well-being and lead to reductions in health disparities. This NOFO requires the inclusion of a resource evaluation plan and evidence of resource sustainability. **Application Due Date:** multiple dates; see announcement. **Expiration Date:** May 26, 2026.



[PAR-24-273](#) – (R01 Clinical Trial Optional)

**Advancing Healthcare for Older adults from Populations that Experience Health Disparities**

The purpose of this initiative is to advance the science and implementation of innovative multi-level health care research for older adults from populations that experience health disparities. The initiative will support research designed to (1) gain a better understanding of appropriate screening, diagnostic, and clinical care guidelines in a primary care setting, (2) explore shared decision-making that is needed to enhance care planning and patient agency between clinicians and care teams with the older adult and their caregiver(s), and (3) identify effective strategies for care coordination. The overarching aim of this NOFO is to identify and understand best practices to engage older adults and their caregivers in providing appropriate care that is central to the attainment of optimal physical and mental health and wellbeing of older adults and the reduction of health disparities in this population. **Application Due Date:** multiple dates; see announcement. **Expiration Date:** January 8, 2028.

[PAR-24-299](#) – (R01 Clinical Trial Optional)

[PAR-24-300](#) – (R34 Clinical Trial Optional)

**Behavioral & Integrative Treatment Development Program**

The NOFO is to encourage research grant applications on the development and testing of behavioral and integrative treatments for drug and alcohol use, misuse, and dependence. This notice in conjunction with the R34 companion NOFO, [PAR-24-300](#)) will support Stages II and III behavioral and integrative intervention research with the goal to advance science, including treatments that are intended to be more efficient, better tailored to individuals, or more readily scalable. **Application Due Date:** February 16, 2025. **Expiration Date:** May 8, 2028.

[PAR-24-301](#) – (P41 Clinical Trial Not Allowed)

**NICHD Resource Program Grants in Bioinformatics**

The purpose of this Notice of Funding Opportunity (NOFO) is to support the continued operation, maintenance, and dissemination of unique knowledge, data, and/or bioinformatics resources that are of major importance to the research community using animal models of embryonic developmental processes. These grants will support ongoing development and enhancement of the resources, user training and services, provision of community generated data storage and curation, wide dissemination of the tools and/or resources, and expansion of interoperability with other NIH bioinformatics resources. **Application Due Date:** multiple dates; see announcement. **Expiration Date:** September 26, 2027.

## NIH Funding Opportunities: Program Announcements (PA)

The following opportunities have standard due dates unless noted otherwise:

[PA-25-080](#) – Reissue of [PA-24-141](#)

**NIH Support for Conferences and Scientific Meetings (Parent R13 Clinical Trial Not Allowed)**

The purpose of the NIH Research Conference Grant (R13) is to support high quality conferences that are relevant to the public health and to the scientific mission of the participating Institutes and Centers. **Application Due Date:** multiple dates; see announcement. **Expiration Date:** September 8, 2027.

[PA-25-121](#) – Reissue of [PAR-22-083](#) (R01 Clinical Trial Not Allowed)

[PA-25-123](#) – Reissue of [PAR-22-084](#) (R21 Clinical Trial Not Allowed)

**Epidemiologic Research on Emerging Risk Factors and Liver Cancer Susceptibility**

The purpose of this funding announcement is to promote epidemiologic research investigating novel and innovative hypotheses on emerging risk factors (biological, environmental, and social) and their interplay with established risk factors (e.g., viral hepatitis) associated with the development of liver cancer (hepatocellular carcinoma and other histological subtypes) in the United States. This NOFO seeks applications focusing on epidemiologic research investigating emerging and new etiologic factors and liver cancer risk in populations relevant to the United States. **Application Due Date (R01):** February 5, 2025; (R21) February 16, 2025. **Expiration Date:** May 8, 2025.



## Limited Submissions

Only one application per institution is allowed for the following FOAs and prior approval from the OVPR is required to be the sole applicant. If interested in applying, please provide the OVPR with notification 60 days prior to the deadline to [ovpr.limitedsubmission@research.buffalo.edu](mailto:ovpr.limitedsubmission@research.buffalo.edu) before proceeding with the application.

### [Limited Submission Funding Opportunities](#)

Prior Research Opportunities can be found on the SPHHP RAS website and by clicking the link below:

### [Research Opportunities from Past Newsletters](#)

## Words to Live By

*A moment of clarity without any action is just a thought that passes in the wind. But a moment of clarity followed by an action is a pivotal moment in our life."*

- Don Miguel Ruiz Jr.

For more information on RAS services, visit our website at [sphhp.buffalo.edu/ras](http://sphhp.buffalo.edu/ras)

